Vertex to acquire viacyte, with the goal of accelerating its potentially curative vx-880 programs in type 1 diabetes

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the company has entered into a definitive agreement under which vertex will acquire viacyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (t1d), for $320 million in cash. “vx-880 has successfully demonstrated clinical proof of concept in t1d, and the acquisition of viacyte will accelerate our
VRTX Ratings Summary
VRTX Quant Ranking